Navigation Links
Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
Date:11/6/2012

CRANBURY, N.J. and CAMBRIDGE, Mass., Nov. 6, 2012 /PRNewswire/ -- Oncobiologics, Inc. and Boston Oncology, LLC today announced a strategic partnership that will allow Boston Oncology to license, manufacture, and commercialize four of Oncobiologics' biosimilar therapies for cancer and immunological disease in the Middle East and North African (MENA) regions.

Under the agreement, Boston Oncology—a pharmaceutical company that localizes advanced technologies and manufacturing expertise in the developing world—will provide Oncobiologics with upfront licensing payments and development milestone payments, along with royalties after the medicines are commercialized. Boston Oncology plans to oversee clinical trials and the development of manufacturing facilities for these therapies in various MENA markets.

The four biosimilars under agreement are generic versions of the most popular therapies in the world for their indications, representing annual global revenue of more than $25 billion.

"This partnership represents a critical step in Boston Oncology's mission to provide people in emerging nations with cost-effective, locally-produced therapeutics for cancers and inflammatory diseases," said Boston Oncology Founder and CEO Abdullah Baaj, M.D., Pharm. D. "Oncobiologics has a rigorous R&D program that will allow us to bring biosimilar therapies to the Middle East and North Africa."

"We are thrilled to announce this strategic alliance with Boston Oncology, which represents the perfect partner for launching Oncobiologics' first four biosimilar molecules in the MENA region," said Pankaj Mohan, Ph.D., CEO of Oncobiologics. "Boston Oncology has built an innovative, forward-looking model that will bring affordable, therapeutically important medicines to emerging markets," he said.

Specific financial terms were not disclosed. 

About Oncobiologics, Inc.
Oncobiologics is a biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts, Oncobiologics operates from a state-of-the-art R&D facility in Cranbury, NJ. Together with its biosimilars licensing partner, Parilis Biopharmaceuticals, Oncobiologics is actively pursuing commercial partner­ship opportunities. For more information, please visit www.oncobiologics.com or call 609-619-3990.

About Boston Oncology, LLC
Boston Oncology, LLC is a privately held company headquartered in Cambridge, Massachusetts, USA. Registered in 2012, Boston Oncology acquires, manages, and transfers intellectual property to locally produce generic chemotherapy and biologic pharmaceuticals in developing nations and emerging markets across the world. Visit www.bostononcology.com. Contact:ONCOBIOLOGICS, INC.BUSINESS & TECHNICAL INQUIRIESStephen J. McAndrew, Ph.D.609-619-3990, ext. 216stephenmcandrew@oncobiologics.com MEDIA INQUIRIESRick Gregory860-677-2377rickgregory@oncobiologics.comBOSTON ONCOLOGY, LLCBUSINESS INQUIRIESZeshawn Beg, DBA, CMACFO, Boston Oncology, LLC617-800-9439zbeg@bostononcology.com MEDIA INQUIRIESSarah Welch DeMayoVibrancy Communications781-727-7516sarah@vibrancycom.com This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael F. Mahoney Assumes Role of Chief Executive Officer and President of Boston Scientific
2. Varian Medical Systems to Proceed with Year End Review and Webcast for Investors at ASTRO Meeting in Boston
3. Boston Scientific to Acquire BridgePoint Medical, Inc.
4. MD+DI Announces Wireless Connectivity in Medical Devices EAST Conference in Boston, MA
5. Boston Scientific to Participate in the 2012 Morgan Stanley Global Healthcare Conference
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
7. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
8. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
9. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
10. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
11. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):